Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions
- PMID: 34095407
- PMCID: PMC8174672
- DOI: 10.3233/blc-190249
Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions
Abstract
Background: A broad, comprehensive review of studies exploring associations between lifestyle factors and non-muscle invasive bladder cancer (NMIBC) outcomes is warranted to consolidate recommendations and identify gaps in research.
Objective: To summarize the literature on associations between lifestyle factors and clinical outcomes among patients with NMIBC.
Methods: PubMed was systematically queried for articles published through March 2019 regarding lifestyle factors and recurrence, progression, cancer-specific mortality, and all-cause mortality among patients with NMIBC.
Results: Notwithstanding many ambiguities, there is good-quality evidence suggesting a benefit of smoking avoidance/cessation, healthy body mass index (BMI), and type II diabetes mellitus prevention and treatment. Lactobacillus casei probiotic supplementation may reduce recurrence. There have been individual studies suggesting a benefit for uncooked broccoli and supplemental vitamin E as well as avoidance of supplemental vitamin B9, areca nut chewing, and a "Western diet" pattern high in fried foods and red meat. Additional studies do not suggest associations between NMIBC outcomes and use of fibrin clot inhibitors; insulin and other oral hypoglycemics; statins; supplemental selenium, vitamin A, vitamin C, and vitamin B6; fluid intake and intake of specific beverages (e.g., alcohol, coffee, green tea, cola); various dietary patterns (e.g., Tex-Mex, high fruit and vegetable, low-fat); and occupational and chemical exposures.
Conclusions: Despite a myriad of publications on lifestyle factors and NMIBC, a need remains for research on unexplored associations (e.g., physical activity) and further studies that can elucidate causal effects. This would inform future implementation strategies for healthy lifestyle change in NMIBC patients.
Keywords: Urinary bladder neoplasms; body mass index; diabetes mellitus; diet; dietary supplements; lifestyle; non-invasive; prognosis; recurrence; smoking.
Conflict of interest statement
CONFLICT OF INTEREST SPP is on the advisory board for BMS; consultant for Photocure. SAK is on the advisory board and is a consultant for Mojo Enterprises Inc. The other authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147. Bladder Cancer. 2018. PMID: 29430510 Free PMC article.
-
Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients.Urol Oncol. 2019 Sep;37(9):573.e1-573.e8. doi: 10.1016/j.urolonc.2019.04.016. Epub 2019 May 8. Urol Oncol. 2019. PMID: 31076356
-
The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer.Urol Oncol. 2015 Feb;33(2):65.e9-17. doi: 10.1016/j.urolonc.2014.06.002. Epub 2014 Jul 9. Urol Oncol. 2015. PMID: 25023787
-
Diet and lifestyle considerations for patients with prostate cancer.Urol Oncol. 2020 Mar;38(3):105-117. doi: 10.1016/j.urolonc.2019.06.018. Epub 2019 Jul 18. Urol Oncol. 2020. PMID: 31327752 Free PMC article. Review.
-
Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle.Curr Opin Urol. 2018 Jan;28(1):88-92. doi: 10.1097/MOU.0000000000000452. Curr Opin Urol. 2018. PMID: 29211694 Review.
Cited by
-
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.Front Oncol. 2024 Oct 21;14:1424293. doi: 10.3389/fonc.2024.1424293. eCollection 2024. Front Oncol. 2024. PMID: 39497708 Free PMC article.
-
Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.Int J Mol Sci. 2025 Jul 29;26(15):7340. doi: 10.3390/ijms26157340. Int J Mol Sci. 2025. PMID: 40806474 Free PMC article. Review.
-
Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts.Cancer Med. 2021 Feb;10(4):1431-1438. doi: 10.1002/cam4.3721. Epub 2021 Jan 16. Cancer Med. 2021. PMID: 33455057 Free PMC article.
-
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer.Bladder Cancer. 2023 Mar 31;9(1):59-71. doi: 10.3233/BLC-220076. eCollection 2023. Bladder Cancer. 2023. PMID: 38994482 Free PMC article.
-
Microbiome and bladder cancer: the role of probiotics in treatment.Future Microbiol. 2025 Jan;20(1):73-90. doi: 10.1080/17460913.2024.2414671. Epub 2024 Oct 24. Future Microbiol. 2025. PMID: 39445447 Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(1):7–34. - PubMed
-
- Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6, Supplement 1):4–34. - PubMed
-
- Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. The Journal of Urology. 1997;158(1):62–7. - PubMed
-
- Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. European Urology. 2012;62(1):118–25. - PubMed
-
- Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology. 2006;49(3):466–77. - PubMed